EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

Connie N Hess iD, Judith Hsia iD, Ian A Carroll iD, Mark R Nehler, Wolfram Ruf iD, David A Morrow iD, Jose C Nicolau iD, Otavio Berwanger, Michael Szarek iD, Warren H Capell, Shilpa Johri, Michael S Pursley und 10 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023

DOI: 10.1161/atvbaha.122.318748 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Connie N Hess und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (C.N.H., J.H., M.S., W.H.C., M.R.B., M.P.B.), University of Colorado, Aurora. Hauptthemen laut MEDLINE: Blood Coagulation Disorders, COVID-19, Venous Thromboembolism, Fibrin Fibrinogen Degradation Products. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thrombo-inflammation is central to COVID-19-associated coagulopathy. TF (tissue factor), a driver of disordered coagulation and inflammation in viral infections, may be a therapeutic target in COVID-19. The safety and efficacy of the novel TF inhibitor rNAPc2 (recombinant nematode anticoagulation protein c2) in COVID-19 are unknown. METHODS: ASPEN-COVID-19 was an international, randomized, open-label, active comparator clinical trial with blinded end point adjudication. Hospitalized patients with COVID-19 and elevated D-dimer levels were randomized 1:1:2 to lower or higher dose rNAPc2 on days 1, 3, and 5 followed by heparin on day 8 or to heparin per local standard of care. In comparisons of the pooled rNAPc2 versus heparin groups, the primary safety end point was major or nonmajor clinically relevant International Society of Thrombosis and Haemostasis bleeding through day 8. The primary efficacy end point was proportional change in D-dimer concentration from baseline to day 8, or discharge if before day 8. Patients were followed for 30 days. RESULTS: Among 160 randomized patients, median age was 54 years, 43.1% were female, and 38.8% had severe baseline COVID-19. There were no significant differences between rNAPc2 and heparin in bleeding or other safety events. Overall, median change in D-dimer was −16.8% (interquartile range, −45.7 to 36.8; P =0.41) with rNAPc2 treatment and −11.2% (−36.0 to 34.4; P =0.91) with heparin ( P intergroup =0.47). In prespecified analyses, in severely ill patients, D-dimer levels tended to increase more within the heparin (median, 29.0% [−14.9 to 145.2]; P =0.02) than the rNAPc2 group (median, 25.9% [−49.1 to 136.4]; P =0.14; P intergroup =0.96); in mildly ill patients, D-dimer levels were reduced within each group with a numerically greater reduction with rNAPc2 versus heparin (rNAPc2 median, −32.7% [−44.7 to 4.3]; P =0.007 and heparin median, −16.8% [−36.0 to 0.5]; P =0.008, P intergroup =0.34). CONCLUSIONS: rNAPc2 treatment in hospitalized patients with COVID-19 was well tolerated without excess bleeding or serious adverse events but did not significantly reduce D-dimer more than heparin at day 8. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04655586.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Coagulation DisordersCOVID-19Venous ThromboembolismFibrin Fibrinogen Degradation ProductsAntifibrinolytic AgentsFemaleHumansMaleMiddle AgedAnticoagulantsHemorrhageHeparinInflammationThromboplastin

Stichwörter der Autor:innen

clinical trialfibrin fragment Dhemorrhageheparinthromboplastin

Substanzen

AnticoagulantsHeparinThromboplastinfibrin fragment DFibrin Fibrinogen Degradation ProductsAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Medicine (C.N.H., J.H., M.S., W.H.C., M.R.B., M.P.B.), University of Colorado, Aurora.
  • CPC Clinical Research, Aurora, CO (C.N.H., J.H., M.R.N., M.S., W.H.C., R.G., M.P.B.).
  • ARCA biopharma, Westminster, CO (I.A.C., D.M., C.A.G., S.P.H., T.K., M.R.B.).
  • Department of Surgery (M.R.N., R.G.), University of Colorado, Aurora.
  • Johannes Gutenberg University Medical Center, Mainz, Germany (W.R.).
  • Scripps Research, La Jolla, CA (W.R.).

ORCID-Profile: Connie N Hess, Judith Hsia, Ian A Carroll, Wolfram Ruf, David A Morrow, Jose C Nicolau, Michael Szarek, Mark B Effron, Sophia P Huebler, Michael R Bristow, Marc P Bonaca

Zitieren

APA

Hess, C. N., Hsia, J., Carroll, I. A., Nehler, M. R., Ruf, W., Morrow, D. A., Nicolau, J. C., Berwanger, O., Szarek, M., Capell, W. H., Johri, S., Pursley, M. S., Gupta, R., Meehan, P. S., Franchi, F., Effron, M. B., Marshall, D., Graybill, C. A., Huebler, S. P., …, & Bonaca, M. P. (2023). Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.122.318748

Vancouver

Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, et al. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.122.318748

BibTeX
@article{Hess2023,
  author = {Hess, Connie N and Hsia, Judith and Carroll, Ian A and Nehler, Mark R and Ruf, Wolfram and Morrow, David A and Nicolau, Jose C and Berwanger, Otavio and Szarek, Michael and Capell, Warren H and Johri, Shilpa and Pursley, Michael S and Gupta, Ryan and Meehan, Patrick S and Franchi, Francesco and Effron, Mark B and Marshall, Debra and Graybill, Christopher A and Huebler, Sophia P and Keuer, Thomas and Bristow, Michael R and Bonaca, Marc P},
  title = {Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  doi = {10.1161/atvbaha.122.318748}
}
Kostenlos starten →